Daha özgün öneriler için "
ile kl> AAO Bilgi Bülteni-
ni okuyunuz.
Aaron L, Saadoun D, Calatroni I, et al. Tuberculosis in HIV-infected patients: a comprehensive
review. Clin Microbiol Infect. 2004;10:388398.
Blasi E, Colombari B, Orsi CF, et al. The human immunodeficiency virus (HIV) protease inhibitor
indinavir directly affects the opportunistic fungal pathogen Cryptococcus neoformans. FEMS
Immunol Med Microbiol. 2004;42:187195.
Borroto-Esoda K, Myrick F, Feng J, et al. In vitro combination of amdoxovir and the inosine
monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates
potent activity against wild-type and drug-resistant variants of human immunodeficiency
virus type 1. Antimicrob Agents Chemother. 2004;48:43874394.
Centers for Disease Control and Prevention. Guidelines for using antiretroviral agents among
HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for
Treatment of HIV. MMWR. 2002;51(No. RR-7). Available at http://www.cdc.gov/mmwr/
PDF/RR/RR5107.pdf. Accessed December 17, 2003.
Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2003 (Vol. 15).
Atlanta: US Department of Health and Human Services, Centers for Disease Control and
Prevention; 2004. Also available at http://www.cdc.gov/hiv/stats/hasrlink.htm.
Chan DJ. HIV-1 superinfection: evidence and impact. Curr HIV Res. 2004;2:271274.
Chapman TM, Plosker GL, Perry CM. Fosamprenavir: a review of its use in the management of
antiretroviral therapynaive patients with HIV infection. Drugs. 2004;64:21012124.
Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected
patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS.
2004;18:11371146.
De Clercq E. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. Int J
Biochem Cell Biol. 2004;36:18001822.
De Clercq E. New anti-HIV agents and targets. Med Res Rev. 2002;22:531565.
Fortin C, Joly V. Efavirenz for HIV-1 infection in adults: an overview. Expert Rev Anti Infect
Ther. 2004;2:671684.
Gallant JE, Pham PA. Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection.
Expert Rev Anti Infect Ther. 2003;1:415422.
Gardner EM, Connick E. Illness of Immune Reconstitution: recognition and management. Curr
Infect Dis Rep. 2004;6:483493.
Gewurz BE, Jacobs M, Proper JA, et al. Capravirine, a nonnucleoside reverse-transcriptase
inhibitor in patients infected with HIV-1: a phase 1 study. J Infect Dis. 2004;190:19571961.
Hartmann P, Rehwald U, Salzberger B, et al. Current treatment strategies for patients with
Hodgkin's lymphoma and HIV infection. Expert Rev Anticancer Ther. 2004;4:401410.
Herman ES, Klotman PE. HIV-associated nephropathy: epidemiology, pathogenesis, and
treatment. Semin Nephrol. 2003;23:200208.
Hu DJ, Vitek CR, Bartholow B, et al. Key issues for a potential human immunodeficiency virus
vaccine. Clin Infect Dis. 2003;36:638644.
Kelly LM, Lisziewicz J, Lori F. "Virostatics" as a potential new class of HIV drugs. Curr Pharm
Des. 2004;10:41034120.
Lange CG, Woolley IJ, Brodt RH. Disseminated Mycobacterium avium-intracellulare complex
(MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?
Drugs. 2004;64(7):679692.
52
·
Genel T>pta Yenilikler